678 related articles for article (PubMed ID: 16339654)
21. A roadmap to safe, efficient, and stable lentivirus-mediated gene therapy with hematopoietic cell transplantation.
Neschadim A; McCart JA; Keating A; Medin JA
Biol Blood Marrow Transplant; 2007 Dec; 13(12):1407-16. PubMed ID: 18022569
[TBL] [Abstract][Full Text] [Related]
22. Stem cell engineering for the treatment of severe hemoglobinopathies.
Sadelain M; Boulad F; Lisowki L; Moi P; Riviere I
Curr Mol Med; 2008 Nov; 8(7):690-7. PubMed ID: 18991654
[TBL] [Abstract][Full Text] [Related]
23. Gene Therapy for beta-thalassemia.
Malik P; Arumugam PI
Hematology Am Soc Hematol Educ Program; 2005; ():45-50. PubMed ID: 16304358
[TBL] [Abstract][Full Text] [Related]
24. Expression of an anti-sickling beta-globin in human erythroblasts derived from retrovirally transduced primitive normal and sickle cell disease hematopoietic cells.
Oh IH; Fabry ME; Humphries RK; Pawliuk R; Leboulch P; Hoffman R; Nagel RL; Eaves C
Exp Hematol; 2004 May; 32(5):461-9. PubMed ID: 15145214
[TBL] [Abstract][Full Text] [Related]
25. Regulated high-level human beta-globin gene expression in erythroid cells following recombinant adeno-associated virus-mediated gene transfer.
Einerhand MP; Antoniou M; Zolotukhin S; Muzyczka N; Berns KI; Grosveld F; Valerio D
Gene Ther; 1995 Jul; 2(5):336-43. PubMed ID: 7671109
[TBL] [Abstract][Full Text] [Related]
26. Gene therapy using hematopoietic stem cells.
Kohn DB
Curr Opin Mol Ther; 1999 Aug; 1(4):437-42. PubMed ID: 11713757
[TBL] [Abstract][Full Text] [Related]
27. Permanent and panerythroid correction of murine beta thalassemia by multiple lentiviral integration in hematopoietic stem cells.
Imren S; Payen E; Westerman KA; Pawliuk R; Fabry ME; Eaves CJ; Cavilla B; Wadsworth LD; Beuzard Y; Bouhassira EE; Russell R; London IM; Nagel RL; Leboulch P; Humphries RK
Proc Natl Acad Sci U S A; 2002 Oct; 99(22):14380-5. PubMed ID: 12391330
[TBL] [Abstract][Full Text] [Related]
28. Long-term expression of gamma-globin mRNA in mouse erythrocytes from retrovirus vectors containing the human gamma-globin gene fused to the ankyrin-1 promoter.
Sabatino DE; Seidel NE; Aviles-Mendoza GJ; Cline AP; Anderson SM; Gallagher PG; Bodine DM
Proc Natl Acad Sci U S A; 2000 Nov; 97(24):13294-9. PubMed ID: 11069298
[TBL] [Abstract][Full Text] [Related]
29. Restoration of the balanced alpha/beta-globin gene expression in beta654-thalassemia mice using combined RNAi and antisense RNA approach.
Xie SY; Ren ZR; Zhang JZ; Guo XB; Wang QX; Wang S; Lin D; Gong XL; Li W; Huang SZ; Zeng F; Zeng YT
Hum Mol Genet; 2007 Nov; 16(21):2616-25. PubMed ID: 17716993
[TBL] [Abstract][Full Text] [Related]
30. The challenge of obtaining therapeutic levels of genetically modified hematopoietic stem cells in beta-thalassemia patients.
Persons DA
Ann N Y Acad Sci; 2010 Aug; 1202():69-74. PubMed ID: 20712775
[TBL] [Abstract][Full Text] [Related]
31. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1.
Hacein-Bey-Abina S; Von Kalle C; Schmidt M; McCormack MP; Wulffraat N; Leboulch P; Lim A; Osborne CS; Pawliuk R; Morillon E; Sorensen R; Forster A; Fraser P; Cohen JI; de Saint Basile G; Alexander I; Wintergerst U; Frebourg T; Aurias A; Stoppa-Lyonnet D; Romana S; Radford-Weiss I; Gross F; Valensi F; Delabesse E; Macintyre E; Sigaux F; Soulier J; Leiva LE; Wissler M; Prinz C; Rabbitts TH; Le Deist F; Fischer A; Cavazzana-Calvo M
Science; 2003 Oct; 302(5644):415-9. PubMed ID: 14564000
[TBL] [Abstract][Full Text] [Related]
32. Gene therapy for homozygous beta-thalassemia. Is it a reality?
Boulad F; Rivière I; Sadelain M
Hemoglobin; 2009; 33 Suppl 1():S188-96. PubMed ID: 20001625
[TBL] [Abstract][Full Text] [Related]
33. Hematopoietic stem cell gene transfer for the treatment of hemoglobin disorders.
Persons DA
Hematology Am Soc Hematol Educ Program; 2009; ():690-7. PubMed ID: 20008255
[TBL] [Abstract][Full Text] [Related]
34. Genotoxicity of retroviral integration in hematopoietic cells.
Nienhuis AW; Dunbar CE; Sorrentino BP
Mol Ther; 2006 Jun; 13(6):1031-49. PubMed ID: 16624621
[TBL] [Abstract][Full Text] [Related]
35. Gene therapy resumes.
Novak K
Nat Rev Cancer; 2002 Nov; 2(11):813. PubMed ID: 12442759
[No Abstract] [Full Text] [Related]
36. The beta-globin locus control region versus gene therapy vectors: a struggle for expression.
Ellis J; Pannell D
Clin Genet; 2001 Jan; 59(1):17-24. PubMed ID: 11168020
[TBL] [Abstract][Full Text] [Related]
37. Use of the hereditary persistence of fetal hemoglobin 2 enhancer to increase the expression of oncoretrovirus vectors for human gamma-globin.
Fragkos M; Anagnou NP; Tubb J; Emery DW
Gene Ther; 2005 Nov; 12(21):1591-600. PubMed ID: 15944728
[TBL] [Abstract][Full Text] [Related]
38. Strategy for a multicenter phase I clinical trial to evaluate globin gene transfer in beta-thalassemia.
Sadelain M; Rivière I; Wang X; Boulad F; Prockop S; Giardina P; Maggio A; Galanello R; Locatelli F; Yannaki E
Ann N Y Acad Sci; 2010 Aug; 1202():52-8. PubMed ID: 20712772
[TBL] [Abstract][Full Text] [Related]
39. Globin gene transfer as a potential treatment for the beta-thalassaemias and sickle cell disease.
Sadelain M
Vox Sang; 2004 Jul; 87 Suppl 2():235-42. PubMed ID: 15209924
[No Abstract] [Full Text] [Related]
40. Extended beta-globin locus control region elements promote consistent therapeutic expression of a gamma-globin lentiviral vector in murine beta-thalassemia.
Hanawa H; Hargrove PW; Kepes S; Srivastava DK; Nienhuis AW; Persons DA
Blood; 2004 Oct; 104(8):2281-90. PubMed ID: 15198957
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
